A phase II trial of interferon alpha‐2A, 5‐fluorouracil, and cisplatin in patients with advanced esophageal carcinoma Academic Article Article uri icon

Overview

MeSH Major

  • Adenoviridae
  • Genetic Vectors
  • Myocardial Ischemia
  • Vascular Endothelial Growth Factor A

abstract

  • In this Phase II trial, the combination of IFN-alpha, 5-FU, and cisplatin had substantial antitumor activity in esophageal carcinoma with apparently greater antitumor activity in epidermoid carcinoma than adenocarcinoma. A larger confirmatory trial comparing this treatment to conventional 5-FU and cisplatin is warranted for epidermoid carcinoma. In future chemotherapy trials, the response assessment for epidermoid and adenocarcinoma should continue to be stratified.

publication date

  • January 1995

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19950501)75:9<2197::AID-CNCR2820750902>3.0.CO;2-S

PubMed ID

  • 7712428

Additional Document Info

start page

  • 2197

end page

  • 202

volume

  • 75

number

  • 9